Lepr Phenotype Annotations - Multigenic Genotypes

Mammalian Phenotype Ontology Annotations
Query Results - Summary

Symbol
Name
ID

Lepr
leptin receptor
MGI:104993

113 phenotypes from multigenic genotypes

Allelic Composition Genetic Background	Annotated Term	Reference
Apoe^tm1Unc/Apoe^tm1Unc Lepr^db/Lepr^db involves: 129P2/OlaHsd * C57BLKS/J	abnormal retina morphology	J:103714
	abnormal retina vasculature morphology	J:103714
Aqp9^tm1Nlsn/Aqp9^tm1Nlsn Lepr^db/Lepr^db involves: 129S1/Sv * C57BL/6 * C57BLKS/J	decreased circulating glucose level	J:123742
	increased circulating glycerol level	J:123742
Ccr2^{tm1.1(CCR2)Rodb}/Ccr2^{tm1.1(CCR2)Rodb} Lepr^db/Lepr^db involves: C57BL/6 * C57BLKS/J	abnormal urine protein level	J:203000
Cdkn1b^tm1Kin/Cdkn1b⁺ Lepr^db/Lepr^db involves: C57BL/6J * C57BLKS/J	abnormal pancreatic islet morphology	J:96047
	decreased body temperature	J:96047
	hyperglycemia	J:96047
	hyperlipidemia	J:96047
	increased circulating insulin level	J:96047
	increased pancreatic beta cell number	J:96047
	obese	J:96047
	polyphagia	J:96047
Cdkn1b^tm1Kin/Cdkn1b^tm1Kin Lepr^db/Lepr^db involves: C57BL/6J * C57BLKS/J	abnormal pancreatic islet morphology	J:96047
	decreased body temperature	J:96047
	hyperlipidemia	J:96047
	increased circulating insulin level	J:96047
	increased pancreatic beta cell number	J:96047
	obese	J:96047
	polyphagia	J:96047
Cebpb^tm1.1Maka/Cebpb^tm1.1Maka Lepr^db/Lepr^db Tg(Ins2-cre)23Herr/0 involves: 129P2/OlaHsd * C57BL/6J * C57BLKS/J * CBA/J	abnormal pancreatic islet cell apoptosis	J:156725
	hyperglycemia	J:156725
	increased circulating insulin level	J:156725
	increased pancreatic beta cell mass	J:156725
Cxcl12^tm1.1Sjm/Cxcl12^tm1.1Sjm Lepr^tm2(cre)Rck/Lepr⁺ involves: C57BL/6	abnormal hematopoietic system morphology/development	J:194748
Dbsq1^C57BLKS/J/Dbsq1^C3H/HeJ Lepr^db/Lepr^db involves: C3H/HeJ * C57BLKS	abnormal fat pad morphology	J:116038
Dbsq1^C57BLKS/J/Dbsq1^C57BLKS/J Lepr^db/Lepr^db involves: C3H/HeJ * C57BLKS	abnormal fat pad morphology	J:116038
Dbsq2^C3H/HeJ/Dbsq2^C3H/HeJ Lepr^db/Lepr⁺ involves: C3H/HeJ * C57BLKS	increased body weight	J:116038
Dbsq2^C57BLKS/J/Dbsq2^C3H/HeJ Lepr^db/Lepr⁺ involves: C3H/HeJ * C57BLKS	increased body weight	J:116038
Dbsq3^C3H/HeJ/Dbsq3^C3H/HeJ Lepr^db/Lepr⁺ involves: C3H/HeJ * C57BLKS	increased circulating glucose level	J:116038
Dbsq3^C57BLKS/J/Dbsq3^C3H/HeJ Lepr^db/Lepr⁺ involves: C3H/HeJ * C57BLKS	increased circulating glucose level	J:116038
Dock7^m/Dock7⁺ Lepr^db/Lepr⁺ BKS.Cg-Dock7^m +/+ Lepr^db/J	extended life span	J:6081
Foxo1^tm2.1Dac/Foxo1^tm2.1Dac Lepr^db/Lepr^db B6.Cg-Foxo1^tm2.1Dac Lepr^db	impaired glucose tolerance	J:179687
	increased circulating insulin level	J:179687
Gcgr^tm1Mjch/Gcgr^tm1Mjch Lepr^tm1Jke/Lepr^tm1Jke involves: 129 * 129X1/SvJ * C57BL/6J * SJL	increased liver triglyceride level	J:216393
	obese	J:216393
Gdf15^tm1Sjl/Gdf15^tm1Sjl Lepr^db/Lepr^db involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BLKS/J	abnormal kidney morphology	J:202996
	albuminuria	J:202996
	glomerulosclerosis	J:202996
	hyperglycemia	J:202996
	increased body weight	J:202996
	increased cholesterol level	J:202996
	increased circulating creatinine level	J:202996
	increased circulating HDL cholesterol level	J:202996
	increased fluid intake	J:202996
	increased food intake	J:202996
	increased heart weight	J:202996
	increased kidney weight	J:202996
	increased liver weight	J:202996
	increased urine glucose level	J:202996
	polyuria	J:202996
Gt(ROSA)26Sor^tm2Sho/Gt(ROSA)26Sor⁺ Lepr^tm1.1Chua/Lepr^tm1.1Chua Nts^tm1(cre)Mgmj/Nts⁺ involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * FVB/N	abnormal nervous system electrophysiology	J:176657
Helz2^tm1Tesa/Helz2^tm1Tesa Lepr^db/Lepr^db involves: C57BL/6 * C57BLKS/J	normal growth/size/body region phenotype	J:218127
Insr^tm1Khn/Insr^tm1Khn Lepr^tm1.1Chua/Lepr^tm1.1Chua Tg(Pomc1-cre)16Lowl/0 involves: 129 * 129S4/SvJae * 129S6/SvEvTac * C57BL/6J * FVB/N	abnormal gonadal fat pad morphology	J:192274
	absent corpus luteum	J:192274
	absent mature ovarian follicles	J:192274
	decreased lean body mass	J:192274
	decreased ovulation rate	J:192274
	hyperglycemia	J:192274
	increased abdominal adipose tissue amount	J:192274
	increased circulating leptin level	J:192274
	increased fat cell size	J:192274
	increased percent body fat/body weight	J:192274
	liver inflammation	J:192274
	ovary inflammation	J:192274
	white adipose tissue inflammation	J:192274
Irs2^tm2Mfw/Irs2^tm2Mfw Irs4^tm1.1Mfw/Y Lepr^tm3(cre)Mgmj/Lepr⁺ involves: 129S1/Sv * 129X1/SvJ * C57BL/6	normal growth/size/body region phenotype	J:221293
	normal homeostasis/metabolism phenotype	J:221293
Jaml^tm1Fnyi/Jaml⁺ Lepr^db/Lepr^db Tg(NPHS2-cre)295Lbh/0 B6.Cg-Lepr^db Jaml^tm1Fnyi Tg(NPHS2-cre)295Lbh	abnormal podocyte morphology	J:300243
	expanded mesangial matrix	J:300243
	increased urine protein level	J:300243
Jaml^tm1Fnyi/Jaml^tm1Fnyi Lepr^db/Lepr^db Tg(NPHS2-cre)295Lbh/0 B6.Cg-Lepr^db Jaml^tm1Fnyi Tg(NPHS2-cre)295Lbh	abnormal podocyte morphology	J:300243
	expanded mesangial matrix	J:300243
	increased urine protein level	J:300243
	renal glomerulus lipidosis	J:300243
Kitl^tm1.1Sjm/Kitl^tm2.1Sjm Lepr^tm2(cre)Rck/Lepr⁺ involves: 129S6/SvEvTac * C57BL/6 * C57BL/Ka * SJL	decreased hematopoietic cell number	J:180431
	enlarged spleen	J:180431
	extramedullary hematopoiesis	J:180431
	spleen hyperplasia	J:180431
Kitl^tm1.1Sjm/Kitl^tm2.1Sjm Lepr^tm2(cre)Rck/Lepr⁺ Tg(Tek-cre)12Flv/0 involves: 129S6/SvEvTac * C3H * C57BL/6 * C57BL/Ka * SJL	decreased bone marrow cell number	J:180431
	decreased hematopoietic cell number	J:180431
	spleen hyperplasia	J:180431
Lep^ob/Lep⁺ Tg(Apoe-Lepr)1Kry/0 involves: C57BL/6J	increased bone mass	J:88655
Lep^ob/Lep⁺ Tg(Apoe-Lepr)1Kry/0 involves: C57BL/6J	increased total body fat amount	J:88655
Lepr^db-dmpg/Lepr^db-dmpg involves: B10.D2-H8^b/Sn * C57BL/6	abnormal pancreatic beta cell morphology	J:83762
	hyperglycemia	J:83762
	increased circulating insulin level	J:83762
	obese	J:83762
Lepr^db-Pas/Lepr^db-Pas involves: DW/Pas	decreased muscle weight	J:174584
	enlarged liver	J:174584
	enlarged spleen	J:174584
	female infertility	J:174584
	hyperglycemia	J:174584
	increased brown adipose tissue amount	J:174584
	increased circulating cholesterol level	J:174584
	increased circulating insulin level	J:174584
	increased total body fat amount	J:174584
	male infertility	J:174584
	obese	J:31095, J:174584
	polyphagia	J:174584
	short femur	J:174584
	short tail	J:174584
Lepr^db-rlpy/Lepr^db-rlpy involves: NU/J	abnormal pancreatic beta cell morphology	J:83762
	hyperglycemia	J:83762
	increased circulating insulin level	J:83762
	obese	J:83762
Lepr^db/Lepr⁺ Tg(APPswe,PSEN1dE9)85Dbo/0 involves: C3H * C57BL/6 * C57BLKS/J	abnormal circulating cholesterol level	J:186924
	amyloidosis	J:186924
	normal growth/size/body region phenotype	J:186924
	impaired glucose tolerance	J:186924
	increased circulating glucose level	J:186924
	increased circulating insulin level	J:186924
	increased pancreatic beta cell mass	J:186924
	insulin resistance	J:186924
Lepr^db/Lepr^db Nos3^tm1Unc/Nos3^tm1Unc BKS.Cg-Lepr^db Nos3^tm1Unc	abnormal kidney afferent arteriole morphology	J:135864
	abnormal nephron morphology	J:135864
	abnormal renal glomerulus morphology	J:135864
	albuminuria	J:135864
	decreased renal glomerular filtration rate	J:135864
	expanded mesangial matrix	J:135864
	glomerulosclerosis	J:135864
	hyperglycemia	J:135864
	increased body weight	J:135864
	increased circulating creatinine level	J:135864
	increased renal glomerulus basement membrane thickness	J:135864
	increased systemic arterial systolic blood pressure	J:135864
	mesangiolysis	J:135864
	renal glomerulus fibrosis	J:135864
Lepr^db/Lepr^db Plin1^tm1Chan/Plin1^tm1Chan involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BLKS/J	decreased susceptibility to age related obesity	J:66267
	increased oxygen consumption	J:66267
Lepr^db/Lepr^db Pten^tm1Hwu/Pten^tm1Hwu Tg(Ins2-cre)25Mgn/0 involves: 129S4/SvJae * C57BL/6 * C57BLKS/J * DBA	abnormal pancreatic islet morphology	J:170206
	normal homeostasis/metabolism phenotype	J:170206
	increased body weight	J:170206
	increased insulin secretion	J:170206
	insulin resistance	J:170206
Lepr^db/Lepr^db Repin1^tm1.2Arte/Repin1^tm1.2Arte involves: BALB/c * C57BL/6 * C57BLKS/J	abnormal adipose tissue physiology	J:238672
	decreased body fat mass	J:238672
	decreased body weight	J:238672
	decreased circulating glucose level	J:238672
	increased insulin sensitivity	J:238672
Lepr^db/Lepr^db Rock1^tm1Leiw/Rock1^tm1Leiw involves: 129S7/SvEvBrd * C57BLKS/J * FVB/N	abnormal mitochondrial physiology	J:182287
	albuminuria	J:182287
	enlarged kidney	J:182287
	expanded mesangial matrix	J:182287
	hyperglycemia	J:182287
	increased body size	J:182287
	increased body weight	J:182287
	increased kidney weight	J:182287
	increased renal glomerulus apoptosis	J:182287
	increased renal glomerulus basement membrane thickness	J:182287
	oxidative stress	J:182287
	normal renal/urinary system phenotype	J:182287
Lepr^db/Lepr^db Serpine1^tm1Mlg/Serpine1^tm1Mlg involves: 129S2/SvPas * C57BL/6 * C57BLKS/J	abnormal enzyme/coenzyme activity	J:127478
	abnormal kidney morphology	J:127478
	abnormal renal glomerulus morphology	J:127478
	albuminuria	J:127478
	decreased body size	J:127478
	hyperglycemia	J:127478
	increased blood urea nitrogen level	J:127478
	obese	J:127478
	premature death	J:127478
Lepr^db/Lepr^db Tg(Fabp4-Fcor)1Jnak/0 involves: C57BL/6 * C57BLKS/J * DBA/2	decreased abdominal adipose tissue amount	J:184684
	decreased body weight	J:184684
	decreased white fat cell size	J:184684
	improved glucose tolerance	J:184684
	increased insulin sensitivity	J:184684
	increased oxygen consumption	J:184684
Lepr^db/Lepr^db Tg(SHBG)4-aGlha/0 involves: C57BL/6 * C57BLKS/J * CBA	abnormal adipose tissue morphology	J:232827
	abnormal blood homeostasis	J:232827
	hepatic steatosis	J:232827
	hyperglycemia	J:232827
	increased circulating cholesterol level	J:232827
	increased circulating free fatty acids level	J:232827
	increased circulating insulin level	J:232827
	increased circulating leptin level	J:232827
	increased circulating testosterone level	J:232827
	increased circulating triglyceride level	J:232827
	increased kidney weight	J:232827
	increased liver triglyceride level	J:232827
	increased liver weight	J:232827
	obese	J:232827
Lepr^{Tg(Mth11)1Aig}/Lepr^{Tg(Mth11)1Aig} involves: Him:OF1	enlarged liver	J:61119
	hyperglycemia	J:61119
	increased circulating insulin level	J:61119
	increased urine glucose level	J:61119
	obese	J:61119
	polydipsia	J:61119
	polyuria	J:61119
Lepr^tm1.2Chua/Lepr^tm1.2Chua Nos1^tm1(cre)Mgmj/Nos1⁺ involves: 129S1/Sv * 129X1/SvJ * C57BL/6	decreased circulating thyroxine level	J:183754
	decreased locomotor activity	J:183754
	decreased oxygen consumption	J:183754
	increased body weight	J:183754
	increased circulating corticosterone level	J:183754
	increased circulating glucose level	J:183754
	increased circulating insulin level	J:183754
	increased circulating leptin level	J:183754
	increased food intake	J:183754
	increased total body fat amount	J:183754
	reduced female fertility	J:183754

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 11/12/2024 MGI 6.24